Table 2.
Entries are average pg/mg protein concentration ± SEM for vehicle-treated control (n=6) and 20μg/kg of 17β-E2 (n=6) treated rats. Values of turnover ratios are multiplied by 10. Data were analyzed by two-way ANOVA (group x neurochemical) in each brain region with two-sample t tests as post hoc comparison. The arrows show significant increase or decrease compared to the control. T p<0.073, *p<0.05, **p<0.01, ***p<0.001. NE, norepinephrine; MHPG, metabolite 3-Methoxy-4-Hydroxyphenylglycol; DA, dopamine; HVA, homovanillic acid; DOPAC, 3-4-dihydroxyphenylalanine; 5-HT, serotonin; 5-HIAA, 5-hydroxyindole acetic acid. Effects of 17β-E2 (20μg/kg) on monoamines, metabolites and turnover ratios in brain areas
| Monoamines Metabolites | Treatment | PFC | CA1 | DG | vDB | Striatum |
|---|---|---|---|---|---|---|
| NE | Control | 3.20 ± 0.19 | 2.04 ± 0.30 | 2.80 ± 0.16 | 2.89 ± 0.23 | 1.67 ± 0.28 |
| E2 | 3.58 ± 0.29 | 1.00 ± 0.15 **↓ | 2.48 ± 0.27 | 2.66 ± 0.20 | 2.12 ± 0.37 | |
| MHPG | Control | 3.11 ± 0.26 | 18.45 ± 2.64 | 3.34 ± 0.35 | 13.18 ± 1.42 | 14.82 ± 1.49 |
| E2 | 6.38 ± 0.41 ***↑ | 12.63 ± 0.69 ⊤↓ | 2.17 ± 0.22 *↓ | 11.35 ± 1.07 | 14.07 ± 0.99 | |
| DA | Control | 0.58 ± 0.09 | 0.46 ± 0.06 | 0.19 ± 0.03 | 20.34 ± 2.82 | 55.26 ± 1.54 |
| E2 | 0.72 ± 0.08 | 0.46 ± 0.07 | 0.20 ± 0.02 | 16.45 ± 2.08 | 69.35 ± 2.37 ***↑ | |
| DOPAC | Control | 0.45 ± 0.05 | 0.15 ± 0.05 | 0.15 ± 0.02 | 1.76 ± 0.25 | 6.10 ± 0.57 |
| E2 | 0.69 ± 0.06 ** ↑ | 0.13 ± 0.03 | 0.15 ± 0.02 | 2.17 ± 0.33 | 7.34 ± 0.63 | |
| HVA | Control | 5.30 ± 0.44 | 0.12 ± 0.02 | 0.09 ± 0.01 | 0.15 ± 0.01 | 0.56 ± 0.07 |
| E2 | 5.83 ± 0.55 | 0.12 ± 0.02 | 0.06 ± 0.01 | 0.24 ± 0.04 | 0.58 ± 0.03 | |
| 5-HT | Control | 2.23 ± 0.23 | 0.71 ± 0.09 | 0.89 ± 0.12 | 2.59 ± 0.20 | 0.76 ± 0.05 |
| E2 | 2.83 ± 0.15 *↑ | 0.79 ± 0.08 | 0.76 ± 0.15 | 2.83 ± 0.40 | 0.72 ± 0.07 | |
| 5-HIAA | Control | 4.09 ± 0.32 | 2.06 ± 0.21 | 2.17 ± 0.22 | 2.28 ± 0.09 | 1.67 ± 0.05 |
| E2 | 4.90 ± 0.29 | 2.20 ± 0.24 | 1.95 ± 0.31 | 2.57 ± 0.29 | 1.67 ± 0.04 | |
| Turnover ratios (× 10) | Treatment | PFC | CA1 | DG | vDB | Striatum |
| MHPG/NE | Control | 9.78 ± 0.76 | 91.47 ± 4.81 | 12.38 ± 1.29 | 46.54 ± 5.15 | 105.55 ± 2.60 |
| E2 | 18.07 ± 1.00 *** ↑ | 105.50 ± 14.43 | 9.10 ± 1.48 | 42.84 ± 2.82 | 78.80 ± 1.61 | |
| HVA/DA | Control | 97.10 ± 10.77 | 3.62 ± 1.06 | 5.02 ± 0.66 | 0.09 ± 0.01 | 0.10 ± 0.00 |
| E2 | 85.18 ± 10.09 | 2.85 ± 0.97 | 3.48 ± 0.36 ⊤↓ | 0.13 ± 0.01 *↑ | 0.09 ± 0.00 | |
| DOPAC/DA | Control | 8.36 ± 1.36 | 5.30 ± 2.50 | 8.98 ± 1.29 | 0.90 ± 0.09 | 1.11 ± 0.01 |
| E2 | 9.90 ± 0.87 | 2.70 ± 0.24 | 8.78 ± 1.24 | 1.32 ± 0.12 *↑ | 1.30 ± 0.03 | |
| 5-HIAA/5-HT | Control | 18.57 ± 0.91 | 31.00 ± 3.87 | 25.73 ± 3.13 | 9.06 ± 0.67 | 22.50 ± 0.17 |
| E2 | 17.50 ± 1.16 | 26.57 ± 1.02 | 27.75 ± 2.71 | 9.81 ± 1.28 | 24.70 ± 0.29 | |